Industry News
Biotechnology Industry News
Aura Biosciences is refocusing…
Aura Biosciences is refocusing under its recently installed CEO, laying off 20% of its employees and overhauling its C-suite as it narrows its focus on ocular oncology.
Infinimmune has amassed further…
Infinimmune has amassed further fuel to power its antibody discovery engine, netting a $75 million series A headlined by Regeneron’s venture arm.
Vaderis Therapeutics has secured…
Vaderis Therapeutics has secured an oversubscribed $152 million series B financing to propel the Swiss biotech's AKT inhibitor through phase 3 with the aim of bringing the first treatment for a rare blood vessel disorder
MoonLake Immunotherapeutics…
MoonLake Immunotherapeutics announced positive phase 3 data for patients with psoriatic arthritis treated with its lead nanobody candidate, sonelokimab.
Jazz Pharmaceuticals is adding to…
Jazz Pharmaceuticals is adding to its orchestra of epilepsy treatments with the acquisition of Actio Biosciences for $820 million upfront.
Sionna Therapeutics has axed a…
Sionna Therapeutics has axed a cystic fibrosis add-on program after flunking a phase 2 trial, eliminating a would-be challenger to Vertex Pharmaceuticals’ empire. The biotech plans to “take actions to preserve capital while evaluating next
AbCellera has reported phase 2…
AbCellera has reported phase 2 results “beyond even the most aggressive upside scenario” that its CEO dared to consider, boosting the biotech’s chances of challenging Astellas and Bayer for a women’s health market.
Sobi has bought into Innate…
Sobi has bought into Innate Pharma’s vision for lacutamab, handing the French biotech $75 million upfront for the rights to market the anti-KIR3DL2 antibody for an aggressive skin cancer.
Arpeggio Biosciences’ eight-year…
Arpeggio Biosciences’ eight-year song has come to an end as the transcriptome biotech’s CEO admitted the company’s Nrf2 program had started to “unravel.”
A phase 2 trial of Silence…
A phase 2 trial of Silence Therapeutics’ divesiran has hit its primary endpoint, emboldening the biotech to gear up for late-phase development of a potential challenger to Takeda and Protagonist Therapeutics’ rusfertide.
Sixty per cent of aTyr Pharma’s…
Sixty per cent of aTyr Pharma’s workforce are heading for the exits as the biotech conserves resources for a second shot at phase 3 success in a type of lung disease.
Novo Nordisk and Amazon Web…
Novo Nordisk and Amazon Web Services will partner to leverage AI and accelerate drug discovery.
Boston biotech Ensoma is doubling…
Boston biotech Ensoma is doubling down on its lead gene therapy for a rare immune disease, laying off another round of employees after previously halving its workforce last November.
Two growing biotechs blasted…
Two growing biotechs blasted through their IPO expectations Friday, with Blossom Hill Therapeutics and Latigo Biotherapeutics each raising at least 30% more than expected in their stock market debuts.
BioMarin Pharmaceutical has ended…
BioMarin Pharmaceutical has ended development of BMN 401 in all indications months after reporting mixed phase 3 data on the rare disease prospect.
After a six-month wait, BioNTech…
After a six-month wait, BioNTech has finally filled its vacant CEO spot with Guido Oelkers, Ph.D. Oelkers hails from his tenure as CEO of Swedish pharma Sobi, where he oversaw the licensing of the respiratory
Following a string of clinical…
Following a string of clinical setbacks, Vistagen’s nasal spray for social anxiety has now failed to top placebo even when given as a double dose. But just like with prior disappointing readouts, the biotech has
Tarsus Pharmaceuticals is fronting…
Tarsus Pharmaceuticals is fronting $450 million to acquire Alkeus Pharmaceuticals for its phase 3-stage retinal disease therapy that's being touted as a potential blockbuster.
BioVie has hailed phase 2 data as…
BioVie has hailed phase 2 data as evidence that bezisterim could represent a “meaningful advance” in the treatment of Parkinson’s disease. But the biotech focused on a new composite measure, rather than its stated primary
Context Therapeutics has stopped…
Context Therapeutics has stopped development of the bispecific T-cell engager CT-95, freeing up cash to extend its runway beyond readouts on its two priority clinical programs.